JP2021527651A5 - - Google Patents
Info
- Publication number
- JP2021527651A5 JP2021527651A5 JP2020570030A JP2020570030A JP2021527651A5 JP 2021527651 A5 JP2021527651 A5 JP 2021527651A5 JP 2020570030 A JP2020570030 A JP 2020570030A JP 2020570030 A JP2020570030 A JP 2020570030A JP 2021527651 A5 JP2021527651 A5 JP 2021527651A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- sarna
- additional activator
- inhibitor
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024087660A JP2024103632A (ja) | 2018-06-15 | 2024-05-30 | Ｃ／ＥＢＰアルファｓａＲＮＡを含む併用療法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862685627P | 2018-06-15 | 2018-06-15 | |
| US62/685,627 | 2018-06-15 | ||
| US201862731532P | 2018-09-14 | 2018-09-14 | |
| US62/731,532 | 2018-09-14 | ||
| US201962821533P | 2019-03-21 | 2019-03-21 | |
| US62/821,533 | 2019-03-21 | ||
| PCT/GB2019/051654 WO2019239144A1 (en) | 2018-06-15 | 2019-06-14 | Combination therapies comprising c/ebp alpha sarna |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024087660A Division JP2024103632A (ja) | 2018-06-15 | 2024-05-30 | Ｃ／ＥＢＰアルファｓａＲＮＡを含む併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021527651A JP2021527651A (ja) | 2021-10-14 |
| JPWO2019239144A5 JPWO2019239144A5 (https=) | 2022-06-20 |
| JP2021527651A5 true JP2021527651A5 (https=) | 2022-06-20 |
Family
ID=67070873
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570030A Pending JP2021527651A (ja) | 2018-06-15 | 2019-06-14 | Ｃ／ＥＢＰアルファｓａＲＮＡを含む併用療法 |
| JP2024087660A Withdrawn JP2024103632A (ja) | 2018-06-15 | 2024-05-30 | Ｃ／ＥＢＰアルファｓａＲＮＡを含む併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024087660A Withdrawn JP2024103632A (ja) | 2018-06-15 | 2024-05-30 | Ｃ／ＥＢＰアルファｓａＲＮＡを含む併用療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210254069A1 (https=) |
| EP (1) | EP3807410A1 (https=) |
| JP (2) | JP2021527651A (https=) |
| CN (1) | CN112543809A (https=) |
| AU (1) | AU2019285344A1 (https=) |
| CA (1) | CA3102334A1 (https=) |
| WO (1) | WO2019239144A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020330133A1 (en) * | 2019-08-14 | 2022-03-17 | Lonza Sales Ag | Extracellular vesicle-ASO constructs targeting CEBP/beta |
| KR20230009354A (ko) * | 2020-05-12 | 2023-01-17 | 아스트라제네카 아베 | 면역 체크포인트 억제제 항체를 사용한 암 치료용 방법 및 조합물 |
| CN111876390B (zh) * | 2020-08-12 | 2021-04-09 | 湖南南华爱世普林生物技术有限公司 | 负载化合物的转基因干细胞外泌体在制备药物或美白化妆品中的用途 |
| EP4329777A1 (en) * | 2021-04-28 | 2024-03-06 | MiNA Therapeutics Limited | Combination therapies comprising c/ebp alpha sarna |
| CN114306367B (zh) * | 2021-08-27 | 2023-03-28 | 赵小洋 | 一种含有C/EBPα-saRNA的组合物 |
| WO2024175887A1 (en) * | 2023-02-22 | 2024-08-29 | Mina Therapeutics Limited | Compositions and methods of using c/ebp alpha sarna |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| AU5613999A (en) | 1998-09-18 | 2000-04-10 | University Of British Columbia, The | Pharmaceutical compositions of vanadium biguanide complexes and their use |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| EP1854880A1 (en) | 1999-03-15 | 2007-11-14 | University of British Columbia | Methods and reagents for modulating cholesterol levels |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1261376A1 (en) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
| CN101928344B (zh) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| US7465446B2 (en) | 2003-05-30 | 2008-12-16 | Medarex, Inc. | Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease |
| CA2604532C (en) | 2005-04-15 | 2017-03-07 | The Regents Of The University Of California | Small activating rna molecules and methods of use |
| JP5066095B2 (ja) | 2005-11-17 | 2012-11-07 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 染色体ｄｎａに標的化されるオリゴマーによる遺伝子発現の調節 |
| US8748815B2 (en) | 2006-08-31 | 2014-06-10 | Hermes Microvision, Inc. | Method and system for detecting or reviewing open contacts on a semiconductor device |
| EP1918376A1 (en) * | 2006-11-03 | 2008-05-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs |
| WO2008063558A2 (en) * | 2006-11-17 | 2008-05-29 | Schering Corporation | Combination of an inhibitor of dna polymerase-alpha and an inhibitor of a checkpoint kinase for proliferative disorders |
| EP2421972A2 (en) | 2009-04-24 | 2012-02-29 | The Board of Regents of The University of Texas System | Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions |
| CN101941001B (zh) | 2009-07-03 | 2014-04-02 | 3M创新有限公司 | 亲水涂层、制品、涂料组合物和方法 |
| WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| KR20130132795A (ko) | 2010-10-08 | 2013-12-05 | 미나 테라퓨틱스 리미티드 | 짧은 rna 분자 |
| EP4060043A1 (en) | 2011-06-21 | 2022-09-21 | MiNA Therapeutics Limited | Albumin production and cell proliferation |
| CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
| CA3236835A1 (en) | 2013-11-22 | 2015-05-28 | Mina Therapeutics Limited | C/ebp alpha short activating rna compositions and methods of use |
| US10912790B2 (en) * | 2015-04-22 | 2021-02-09 | Mina Therapeutics Limited | C/EBP alpha saRNA compositions and methods of use |
| ES2972458T3 (es) * | 2016-02-10 | 2024-06-12 | Bioinvent Int Ab | Combinación de anticuerpo humano anti-FGFR4 y sorafenib |
| WO2018049233A1 (en) * | 2016-09-08 | 2018-03-15 | Nicolas Stransky | Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors |
-
2019
- 2019-06-14 AU AU2019285344A patent/AU2019285344A1/en not_active Abandoned
- 2019-06-14 EP EP19733859.3A patent/EP3807410A1/en active Pending
- 2019-06-14 CA CA3102334A patent/CA3102334A1/en active Pending
- 2019-06-14 WO PCT/GB2019/051654 patent/WO2019239144A1/en not_active Ceased
- 2019-06-14 CN CN201980040237.3A patent/CN112543809A/zh active Pending
- 2019-06-14 US US17/252,593 patent/US20210254069A1/en not_active Abandoned
- 2019-06-14 JP JP2020570030A patent/JP2021527651A/ja active Pending
-
2024
- 2024-05-30 JP JP2024087660A patent/JP2024103632A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527651A5 (https=) | ||
| Kružliak et al. | Vascular endothelial growth factor inhibitor–induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors | |
| JP2018536689A5 (https=) | ||
| SG10201903290YA (en) | Modified double-stranded rna agents | |
| JP2017537070A5 (https=) | ||
| KR20170139055A (ko) | 백금계 항암제에 의해 유도된 세포 내 증가된 p53 수준을 유지시키는 방법 및 이의 활용 | |
| JP2012505660A5 (https=) | ||
| RU2017120536A (ru) | Способы и композиции для модулирования экспрессии аполипопротеина (а) | |
| Sun et al. | Blockade of cholecystokinin-2 receptor and cyclooxygenase-2 synergistically induces cell apoptosis, and inhibits the proliferation of human gastric cancer cells in vitro | |
| JP2019506862A5 (https=) | ||
| JP2019512543A5 (https=) | ||
| Qian et al. | Identification of nicotinic acetylcholine receptor subunits in different lung cancer cell lines and the inhibitory effect of alpha-conotoxin TxID on lung cancer cell growth | |
| JP2017536408A5 (https=) | ||
| JP2020537695A (ja) | ストレプトニグリンおよびラパマイシンを有効成分として含む、癌の予防または治療用薬学的組成物 | |
| Zhou et al. | Long noncoding RNA ZFAS1 promotes hepatocellular carcinoma proliferation by epigenetically repressing miR-193a-3p. | |
| Kelly et al. | Chemotherapy in metastatic colorectal cancer | |
| RU2535993C2 (ru) | Молекула rnai, нацеливающая тимидилатсинтазу и ее применение | |
| Du et al. | Kaempferide enhances type I interferon signaling as a novel broad-spectrum antiviral agent | |
| Jian et al. | A nti‐lymphangiogenesis effects of a specific anti‐interleukin 7 receptor antibody in lung cancer model in vivo | |
| JPWO2019239144A5 (https=) | ||
| Claude-Taupin et al. | Use of epigenetic modulators as a powerful adjuvant for breast cancer therapies | |
| Naeim et al. | A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer | |
| JP2016533190A5 (https=) | ||
| JP2021500026A5 (https=) | ||
| Tong et al. | Recombinant nematode anticoagulant protein c2 inhibits cell invasion by decreasing uPA expression in NSCLC cells |